Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | CA12 | O43570 | 3/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.59 |
| ▸ | CA9 | Q16790 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8139355 | 1.00 | NPC1 (0.64) | NPC1CA12CA1CA2CA9 | |
| SCHEMBL84810 | 0.98 | NPC1 (0.61) | NPC1CA12CA1CA2CA9 | |
| SCHEMBL18361885 | 0.94 | NPC1 (0.56) | NPC1CA12CA1CA2CA9 | |
| SCHEMBL13306274 | 0.89 | — | — | |
| SCHEMBL4781902 | 0.89 | NPSR1 (0.60) | NPC1CA12CA1CA2CA9 | |
| SCHEMBL13453975 | 0.88 | SMN1; SMN2 (0.52) | NPC1CA12CA1CA2CA9 | |
| SCHEMBL8761519 | 0.88 | SMN1; SMN2 (0.52) | NPC1CA12CA1CA2CA9 | |
| SCHEMBL5504349 | 0.86 | DRD2 (0.55) | NPC1ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL3251521 | 0.86 | MAPK1 (0.52) | NPC1CA12CA1CA2CA9 | |
| SCHEMBL25480226 | 0.86 | KDM4E (0.54) | NPC1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | claimed |
| WO-2023229380-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2023-11-30 | — | — | WO | claimed |
| US-8148537-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2012-04-03 | — | — | US | claimed |
| EP-2125736-B1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA AS (DK) | 2011-03-30 | — | — | EP | claimed |
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA (DK) | 2010-02-11 | — | — | US | claimed |
| EP-2125736-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | Leo Pharma A/S (DK) | 2009-12-02 | — | — | EP | claimed |
| WO-2008077404-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA A/S (DK) | 2008-07-03 | — | — | WO | claimed |
| WO-2006089874-A1 | BENZO[2,3]AZEPINO[4,5-B]INDOL-6-ONES | GPC BIOTECH AG (DE) | 2006-08-31 | — | — | WO | claimed |
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| US-20260022126-A1 | 2-(L,8-DIETHYL-1,3,4,9-TETRAHYDROPYRANO[3,4-B]INDOL-1-YL)-N-(2-(PIPERIDIN-1 YL)ETHYL)ACETAMIDE ETODOLAC DERIVATIVE AS A EUKARYOTIC ELONGATION FACTOR 2 KINASE (EEF2K) INHIBITOR FOR TARGETED CANCER THERAPY | BAHCESEHIR UNIVERSITESI (TR) | 2026-01-22 | — | — | US | disclosed |
| WO-2024248763-A1 | NOVEL 2-(L,8-DIETHYL-1,3,4,9-TETRAHYDROPYRANO[3,4-B]INDOL-1-YL)-N-(2-(PIPERIDIN-1 YL)ETHYL)ACETAMIDE ETODOLAC DERIVATIVE AS A EUKARYOTIC ELONGATION FACTOR 2 KINASE (EEF2K) INHIBITOR FOR TARGETED CANCER THERAPY | COMERT ONDER FERAH (TR) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024248763-A1 | NOVEL 2-(L,8-DIETHYL-1,3,4,9-TETRAHYDROPYRANO[3,4-B]INDOL-1-YL)-N-(2-(PIPERIDIN-1 YL)ETHYL)ACETAMIDE ETODOLAC DERIVATIVE AS A EUKARYOTIC ELONGATION FACTOR 2 KINASE (EEF2K) INHIBITOR FOR TARGETED CANCER THERAPY | COMERT ONDER FERAH (TR) | 2024-12-05 | — | — | WO | disclosed |
| WO-2023229380-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2023-11-30 | — | — | WO | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| WO-2006056930-A2 | NOVEL 4 -AMINOPIPERIDINE DERIVATIVES AS PLASMEPSIN II INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-06-01 | — | — | WO | disclosed |
| WO-2003053915-A2 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2003-07-03 | — | — | WO | disclosed |
| EP-0192255-B1 | BIS-2H-PYRROLIDINE DIONES | CIBA-GEIGY AG (CH) | 1990-08-08 | — | — | EP | disclosed |
| US-4789674-A | ALZHEIMER'S DISEASE, MEMORY, DEMENTIA | CIBA-GEIGY CORPORATION (US) | 1988-12-06 | — | — | US | disclosed |
| EP-0192255-A2 | Bis-2H-pyrrolidine diones | CIBA-GEIGY AG (CH) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | NPC1 239/4885CA12 4761/4885CA1 4833/4885 |
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE3B | NPC1 2847/4885CA12 2438/4885CA1 1828/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | NPC1 2385/4885CA12 4708/4885CA1 4869/4885 |
| US-20260022126-A1 | 2-(L,8-DIETHYL-1,3,4,9-TETRAHYDROPYRANO[3,4-B]INDOL-1-YL)-N-(2-(PIPERIDIN-1 YL)ETHYL)ACETAMIDE ETODOLAC DERIVATIVE AS A EUKARYOTIC ELONGATION FACTOR 2 KINASE (EEF2K) INHIBITOR FOR TARGETED CANCER THERAPY | EEF2K, EEF2, EEF1A2 | NPC1 4686/4885CA12 4561/4885CA1 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.